MedTrace Logo

Single and Multiple Dose Pharmacokinetics (PK) of Aramchol From an Aramchol Meglumine Tablet

NCT07251712 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-03-17

No results posted yet for this study

Summary

Evaluate the exposure of of Aramchol from 2 different single doses of Aramchol meglumine tablet and to compare the exposure of steady state from a selected dose of Aramchol meglumine tablet.

Conditions

  • Healthy

Interventions

DRUG

Aramchol

Aramchol tablet at 2 different single doses

Sponsors & Collaborators

  • Galmed Pharmaceuticals Ltd

    lead INDUSTRY

Principal Investigators

  • Christina Yeung, MBBS · Hammersmith Medicines Research

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2025-12-25
Primary Completion
2026-04-15
Completion
2026-05-15
FDA Drug
Yes

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07251712 on ClinicalTrials.gov